Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016 (2016), Article ID 3064643, 11 pages
http://dx.doi.org/10.1155/2016/3064643
Review Article

Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays

1CROM, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, Naples, Italy
2Center of Medical Informatics, SIM/AOU, Second University of Naples, Naples, Italy
3Direzione Scientifica, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, Naples, Italy

Received 12 March 2016; Revised 19 September 2016; Accepted 27 October 2016

Academic Editor: Constantino López-Macías

Copyright © 2016 Francesca Capone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr., and K. W. Kinzler, “Cancer genome landscapes,” Science, vol. 340, no. 6127, pp. 1546–1558, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Versteeg, “Cancer: tumours outside the mutation box,” Nature, vol. 506, no. 7489, pp. 438–439, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. S. C. Mack, H. Witt, R. M. Piro et al., “Epigenomic alterations define lethal CIMP-positive ependymomas of infancy,” Nature, vol. 506, pp. 445–450, 2014. View at Publisher · View at Google Scholar
  4. M. Parker, K. M. Mohankumar, C. Punchihewa et al., “C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma,” Nature, vol. 506, pp. 451–455, 2014. View at Google Scholar
  5. S. Costantini, F. Capone, E. Guerriero, and G. Castello, “An approach for understanding the inflammation and cancer relationship,” Immunology Letters, vol. 126, no. 1-2, pp. 91–92, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Hamilton and P. P. Tak, “The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases,” Arthritis & Rheumatism, vol. 60, no. 5, pp. 1210–1221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Blaser, C. Dostert, T. W. Mak, and D. Brenner, “TNF and ROS crosstalk in inflammation,” Trends in Cell Biology, vol. 26, no. 4, pp. 249–261, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Takeuchi and S. Akira, “Pattern recognition receptors and inflammation,” Cell, vol. 140, no. 6, pp. 805–820, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Qiao, E. G. Giannopoulou, C. H. Chan et al., “Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling,” Immunity, vol. 39, no. 3, pp. 454–469, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. X. Hu and L. B. Ivashkiv, “Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases,” Immunity, vol. 31, no. 4, pp. 539–550, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Germano, P. Allavena, and A. Mantovani, “Cytokines as a key component of cancer-related inflammation,” Cytokine, vol. 43, no. 3, pp. 374–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Mlecnik, G. Bindea, A. Kirilovsky et al., “The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis,” Science Translational Medicine, vol. 8, no. 327, Article ID 327ra26, 2016. View at Publisher · View at Google Scholar
  14. S. E. Church and J. Galon, “Tumor microenvironment and immunotherapy: the whole picture is better than a glimpse,” Immunity, vol. 43, no. 4, pp. 631–633, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. T. T. Nguyen, S. E. Calvano, S. F. Lowry, and I. P. Androulakis, “An agent-based model of cellular dynamics and circadian variability in human endotoxemia,” PLoS ONE, vol. 8, no. 1, Article ID e55550, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Barrera, E. Montes-Servín, A. Barrera et al., “Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis,” Annals of Oncology, vol. 26, no. 2, pp. 428–435, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Miele, A. Sharma, F. Capone et al., “CytReD: a database collecting human cytokinome information,” Bioinformation, vol. 6, no. 5, pp. 207–208, 2011. View at Publisher · View at Google Scholar
  18. S. Costantini, G. Castello, and G. Colonna, “Human cytokinome: a new challenge for systems biology,” Bioinformation, vol. 5, no. 4, pp. 166–167, 2010. View at Publisher · View at Google Scholar
  19. F. Capone, E. Guerriero, G. Colonna et al., “Cytokinome profile evaluation in patients with hepatitis C virus infection,” World Journal of Gastroenterology, vol. 20, no. 28, pp. 9261–9269, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Purohit, S. P. Newman, and M. J. Reed, “The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer,” Breast Cancer Research, vol. 4, no. 2, pp. 65–69, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Panis and W. R. Pavanelli, “Cytokines as mediators of pain-related process in breast cancer,” Mediators of Inflammation, vol. 2015, Article ID 129034, 6 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. V. R. Preedy and R. Hunter, Cytokines Series on Modern Insights into Disease from Molecules to Man, CRC Press, Boca Raton, Fla, USA, 1st edition, 2011.
  23. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Panis, V. J. Victorino, A. C. S. A. Herrera et al., “Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer,” Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 881–888, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Nicolini, A. Carpi, and G. Rossi, “Cytokines in breast cancer,” Cytokine and Growth Factor Reviews, vol. 17, no. 5, pp. 325–337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Esquivel-Velázquez, P. Ostoa-Saloma, M. I. Palacios-Arreola, K. E. Nava-Castro, J. I. Castro, and J. Morales-Montor, “The role of cytokines in breast cancer development and progression,” Journal of Interferon & Cytokine Research, vol. 35, no. 1, pp. 1–16, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. A. Dehqanzada, C. E. Storrer, M. T. Hueman et al., “Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using luminex technology,” Oncology Reports, vol. 17, no. 3, pp. 687–694, 2007. View at Google Scholar · View at Scopus
  28. R. Sankaranarayanan and J. Ferlay, “Worldwide burden of gynaecological cancer: the size of the problem,” Best Practice & Research: Clinical Obstetrics & Gynaecology, vol. 20, no. 2, pp. 207–225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. G. C. Jayson, E. C. Kohn, H. C. Kitchener, and J. A. Ledermann, “Ovarian cancer,” The Lancet, vol. 384, no. 9951, pp. 1376–1388, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. R. C. Bast Jr., “Status of tumor markers in ovarian cancer screening,” Journal of Clinical Oncology, vol. 21, supplement 10, pp. 200S–205S, 2003. View at Google Scholar · View at Scopus
  31. E. Gorelik, D. P. Landsittel, A. M. Marrangoni et al., “Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 4, pp. 981–987, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Matte, D. Lane, C. Laplante et al., “Profiling of cytokines in human epithelial ovarian cancer ascites,” American Journal of Cancer Research, vol. 2, no. 5, pp. 566–580, 2012. View at Google Scholar
  33. M. S. Shiels, R. M. Pfeiffer, A. Hildesheim et al., “Circulating inflammation markers and prospective risk for lung cancer,” Journal of the National Cancer Institute, vol. 105, no. 24, pp. 1871–1880, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Bodelon, M. Y. Polley, T. J. Kemp et al., “Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer,” Annals of Oncology, vol. 24, no. 8, pp. 2073–2079, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. S. R. Pine, L. E. Mechanic, L. Enewold et al., “Increased levels of circulating interleukin 6, interleukin 8, c-reactive protein, and risk of lung cancer,” Journal of the National Cancer Institute, vol. 103, no. 14, pp. 1112–1122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Barrera, E. Montes-Servín, A. Barrera et al., “Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis,” Annals of Oncology, vol. 26, no. 2, pp. 428–435, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Kantola, K. Klintrup, J. P. Väyrynen et al., “Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma,” British Journal of Cancer, vol. 107, no. 10, pp. 1729–1736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. Z.-Y. Chen, K. Raghav, C. H. Lieu et al., “Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer,” British Journal of Cancer, vol. 112, pp. 1088–1097, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Capone, E. Guerriero, G. Colonna et al., “The cytokinome profile in patients with hepatocellular carcinoma and type 2 diabetes,” PLoS ONE, vol. 10, no. 7, Article ID e0134594, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. Z. R. Yurkovetsky, J. M. Kirkwood, H. D. Edington et al., “Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b,” Clinical Cancer Research, vol. 13, no. 8, pp. 2422–2428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Yamaoka, T. Kodama, M. Kita, J. Imanishi, K. Kashima, and D. Y. Graham, “Relation between cytokines and Helicobacter pylori in gastric cancer,” Helicobacter, vol. 6, no. 2, pp. 116–124, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Epplein, Y.-B. Xiang, Q. Cai et al., “Circulating cytokines and gastric cancer risk,” Cancer Causes and Control, vol. 24, no. 12, pp. 2245–2250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Bellone, A. Turletti, E. Artusio et al., “Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients,” The American Journal of Pathology, vol. 155, no. 2, pp. 537–547, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. R. F. Gabitass, N. E. Annels, D. D. Stocken, H. A. Pandha, and G. W. Middleton, “Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13,” Cancer Immunology, Immunotherapy, vol. 60, no. 10, pp. 1419–1430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. W. Błogowski, A. Deskur, M. Budkowska et al., “Selected cytokines in patients with pancreatic cancer: a preliminary report,” PLoS ONE, vol. 9, no. 5, Article ID e97613, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Negrier, D. Perol, C. Menetrier-Caux et al., “Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6—from the Groupe Français d'Immunothérapie,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2371–2378, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. A. J. Montero, C. M. Diaz-Montero, R. E. Millikan et al., “Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-α: association of pretreatment serum levels with survival,” Annals of Oncology, vol. 20, no. 10, pp. 1682–1687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Polimeno, M. Napolitano, S. Costantini et al., “Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma,” BJU International, vol. 112, no. 5, pp. 686–696, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Linkov, R. L. Ferris, Z. Yurkovetsky et al., “Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases,” Proteomics—Clinical Applications, vol. 2, no. 12, pp. 1575–1585, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. X. Provatopoulou, D. Georgiadou, T. N. Sergentanis et al., “Interleukins as markers of inflammation in malignant and benign thyroid disease,” Inflammation Research, vol. 63, no. 8, pp. 667–674, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Tazaki, N. Shimizu, R. Tanaka et al., “Serum cytokine profiles in patients with prostate carcinoma,” Experimental and Therapeutic Medicine, vol. 2, no. 5, pp. 887–891, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. M. S. Block, M. J. Maurer, K. Goergen et al., “Plasma immune analytes in patients with epithelial ovarian cancer,” Cytokine, vol. 73, no. 1, pp. 108–113, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. Z. Chen, C. M. Fillmore, P. S. Hammerman, C. F. Kim, and K.-K. Wong, “Non-small-cell lung cancers: a heterogeneous set of diseases,” Nature Reviews Cancer, vol. 14, no. 8, pp. 535–546, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. A. K. Chaturvedi, T. J. Kemp, R. M. Pfeiffer et al., “Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 9, pp. 1902–1911, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Seruga, H. Zhang, L. J. Bernstein, and I. F. Tannock, “Cytokines and their relationship to the symptoms and outcome of cancer,” Nature Reviews Cancer, vol. 8, no. 11, pp. 887–899, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. Z.-Y. Chen, W.-Z. He, L.-X. Peng et al., “A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients,” International Journal of Cancer, vol. 136, no. 3, pp. 584–592, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Krzystek-Korpacka, D. Diakowska, B. Kapturkiewicz, M. Bebenek, and A. Gamian, “Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance,” Cancer Letters, vol. 337, no. 1, pp. 107–114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Sherman, “Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis,” Seminars in Liver Disease, vol. 30, no. 1, pp. 3–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Nordenstedt, D. L. White, and H. B. El-Serag, “The changing pattern of epidemiology in hepatocellular carcinoma,” Digestive and Liver Disease, vol. 42, supplement 3, pp. S206–S214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Baffy, “Editorial: hepatocellular carcinoma in type 2 diabetes: more than meets the eye,” American Journal of Gastroenterology, vol. 107, no. 1, pp. 53–55, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. D. E. Godar, “Worldwide increasing incidences of cutaneous malignant melanoma,” Journal of Skin Cancer, vol. 2011, Article ID 858425, 6 pages, 2011. View at Publisher · View at Google Scholar
  63. A. Niezgoda, P. Niezgoda, and R. Czajkowski, “Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy,” BioMed Research International, vol. 2015, Article ID 851387, 16 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Shetty, G. M. Beasley, S. Sparks et al., “Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion,” Annals of Surgical Oncology, vol. 20, no. 4, pp. 1128–1135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Ernst, “Review article: the role of inflammation in the pathogenesis of gastric cancer,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 1, pp. 13–18, 1999. View at Publisher · View at Google Scholar · View at Scopus
  66. D. Yadav and A. B. Lowenfels, “The epidemiology of pancreatitis and pancreatic cancer,” Gastroenterology, vol. 144, no. 6, pp. 1252–1261, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. American Cancer Society Cancer Facts & Figures, 2015, http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
  68. S. K. Pal, D. M. S. Hossain, Q. Zhang et al., “Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile,” Journal of Urology, vol. 193, no. 4, pp. 1114–1121, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. R. M. Tuttle, H. Tala, J. Shah et al., “Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system,” Thyroid, vol. 20, no. 12, pp. 1341–1349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Stassi, M. Todaro, M. Zerilli et al., “Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10,” Cancer Research, vol. 63, no. 20, pp. 6784–6790, 2003. View at Google Scholar · View at Scopus
  71. C. Ghoneim, M. Soula-Rothhut, C. Blanchevoye, L. Martiny, F. Antonicelli, and B. Rothhut, “Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion,” Journal of Biological Chemistry, vol. 282, no. 21, pp. 15490–15497, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. C. O. Madu and Y. Lu, “Novel diagnostic biomarkers for prostate cancer,” Journal of Cancer, vol. 1, no. 1, pp. 150–177, 2010. View at Google Scholar · View at Scopus
  73. H. Salman, Y. Ori, M. Bergman, M. Djaldetti, and H. Bessler, “Human prostate cancer cells induce inflammatory cytokine secretion by peripheral blood mononuclear cells,” Biomedicine & Pharmacotherapy, vol. 66, no. 5, pp. 330–333, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Zhang, S.-K. Sun, L.-X. Shi, and X. Zhang, “Serum cytokine profiling of prostate cancer and benign prostatic hyperplasia using recombinant antibody microarray,” Zhonghua nan ke xue, vol. 16, no. 7, pp. 584–588, 2010. View at Google Scholar · View at Scopus
  75. I. B. McInnes and G. Schett, “The pathogenesis of rheumatoid arthritis,” The New England Journal of Medicine, vol. 365, no. 23, pp. 2205–2219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Schett, D. Elewaut, I. B. McInnes, J.-M. Dayer, and M. F. Neurath, “How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy,” Nature Medicine, vol. 19, no. 7, pp. 822–824, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Semerano, E. Minichiello, N. Bessis, and M.-C. Boissier, “Novel immunotherapeutic avenues for rheumatoid arthritis,” Trends in Molecular Medicine, vol. 22, no. 3, pp. 214–229, 2016. View at Publisher · View at Google Scholar · View at Scopus
  78. E. S. Chung, M. Packer, K. H. Lo, A. A. Fasanmade, and J. T. Willerson, “Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure,” Circulation, vol. 107, pp. 3133–3140, 2003. View at Publisher · View at Google Scholar · View at Scopus